Research ExplorerPublicationsSodium Butyrate Increases Expression of the Coxsackie and Ad...

Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells.

Standard

Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells. / Küster, Katrin; Grötzinger, Carsten; Koschel, Annika; Fischer, Andreas; Wiedenmann, Bertram; Anders, Mario.

In: CANCER INVEST, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Küster, K, Grötzinger, C, Koschel, A, Fischer, A, Wiedenmann, B & Anders, M 2009, 'Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells.', CANCER INVEST. <http://www.ncbi.nlm.nih.gov/pubmed/19863349?dopt=Citation>

APA

Küster, K., Grötzinger, C., Koschel, A., Fischer, A., Wiedenmann, B., & Anders, M. (2009). Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells. CANCER INVEST. http://www.ncbi.nlm.nih.gov/pubmed/19863349?dopt=Citation

Vancouver

Küster K, Grötzinger C, Koschel A, Fischer A, Wiedenmann B, Anders M. Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells. CANCER INVEST. 2009.

Bibtex

@article{1c3165cf959841d3928fc6a5e3270a71,
title = "Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells.",
abstract = "ABSTRACT Histone deacetylase inhibitors (HDACI), e.g., sodium butyrate (NaB), have been suggested to upregulate the coxsackie and adenovirus receptor (CAR). Its impact on CAR in colon carcinomas, however, is poorly understood. NaB treatment of colon cancer cells increased CAR expression preferentially in cell lines with low basic CAR levels. These findings suggest that downregulation of CAR gene expression is mediated by transcriptional regulation and that activation of the CAR gene promoter is modulated by histone acetylation. The employment of HDACI may, therefore, represent a promising approach for improving adenovirus-based therapies of colon cancers with low CAR expression levels.",
author = "Katrin K{\"u}ster and Carsten Gr{\"o}tzinger and Annika Koschel and Andreas Fischer and Bertram Wiedenmann and Mario Anders",
year = "2009",
language = "Deutsch",
journal = "CANCER INVEST",
issn = "0735-7907",
publisher = "informa healthcare",

}

RIS

TY - JOUR

T1 - Sodium Butyrate Increases Expression of the Coxsackie and Adenovirus Receptor in Colon Cancer Cells.

AU - Küster, Katrin

AU - Grötzinger, Carsten

AU - Koschel, Annika

AU - Fischer, Andreas

AU - Wiedenmann, Bertram

AU - Anders, Mario

PY - 2009

Y1 - 2009

N2 - ABSTRACT Histone deacetylase inhibitors (HDACI), e.g., sodium butyrate (NaB), have been suggested to upregulate the coxsackie and adenovirus receptor (CAR). Its impact on CAR in colon carcinomas, however, is poorly understood. NaB treatment of colon cancer cells increased CAR expression preferentially in cell lines with low basic CAR levels. These findings suggest that downregulation of CAR gene expression is mediated by transcriptional regulation and that activation of the CAR gene promoter is modulated by histone acetylation. The employment of HDACI may, therefore, represent a promising approach for improving adenovirus-based therapies of colon cancers with low CAR expression levels.

AB - ABSTRACT Histone deacetylase inhibitors (HDACI), e.g., sodium butyrate (NaB), have been suggested to upregulate the coxsackie and adenovirus receptor (CAR). Its impact on CAR in colon carcinomas, however, is poorly understood. NaB treatment of colon cancer cells increased CAR expression preferentially in cell lines with low basic CAR levels. These findings suggest that downregulation of CAR gene expression is mediated by transcriptional regulation and that activation of the CAR gene promoter is modulated by histone acetylation. The employment of HDACI may, therefore, represent a promising approach for improving adenovirus-based therapies of colon cancers with low CAR expression levels.

M3 - SCORING: Zeitschriftenaufsatz

JO - CANCER INVEST

JF - CANCER INVEST

SN - 0735-7907

ER -